Quick Answer
Unicycive Therapeutics, Inc. reported Total Assets of $49.13 million for fiscal year 2025.
Unicycive Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $49.13M | +55.2% |
| 2024 | $31.67M | +123.2% |
| 2023 | $14.19M | +403.6% |
| 2022 | $2.82M | -85.0% |
| 2021 | $18.74M | +9088.2% |
| 2020 | $204.0K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.61M | +31.2% | +68.7% |
| June 30, 2025 | $30.00M | -32.9% | +7.3% |
| March 31, 2025 | $27.95M | -46.7% | -11.8% |
| December 31, 2024 | $31.67M | +123.2% | -17.9% |
| September 30, 2024 | $38.57M | +98.4% | -13.7% |
| June 30, 2024 | $44.70M | +95.3% | -14.7% |
| March 31, 2024 | $52.38M | +92.6% | +269.1% |
| December 31, 2023 | $14.19M | +403.6% | -27.0% |
- Unicycive Therapeutics, Inc. showed an increase of +55.2% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Unicycive Therapeutics, Inc.’s total assets has grown by 23985.8% (from $204.0 thousand to $49.13 million).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: